Publikationen Aichem

Publikationen PD Dr. Annette Aichem

Saxena K, Roverato ND, Reithmann M, Mah MM, Schregle R, Schmidtke G, Silbern I, Urlaub H, Aichem A. 2023. FAT10 is phosphorylated by IKKß to inhibit the antiviral type-I interferon response. Life Sci Alliance Nov 8;7(1):e202101282. doi: 10.26508/lsa.202101282. Print 2024 Jan.
Schnell L, Zubrod A, Catone N, Aichem A. 2023. Tumor necrosis factor mediates USE1-independent FAT10ylation under inflammatory conditions. Life Sci Alliance Aug 21;6(11):e202301985. doi: 10.26508/lsa.202301985. Print 2023 Nov.
Mueller S, Bialas J, Ryu S, Catone N, Aichem A. 2023. The ubiquitin-like modifier FAT10 covalently modifies HUWE1 and strengthens the interaction of AMBRA1 and HUWE1. PLoS One Aug 14;18(8):e0290002. doi: 10.1371/journal.pone.0290002. eCollection 2023.
Brockmann F, Catone N, Wünsch C, Offensperger F, Scheffner M, Schmidtke G, Aichem A. 2023. FAT10 and NUB1L cooperate to activate the 26S proteasome. Life Sci Alliance . May 15;6(8):e202201463. doi: 10.26508/lsa.202201463. Print 2023 Aug.
Roverato ND, Sailer C, Catone N, Aichem A, Stengel F, Groettrup M. 2021. Parkin is an E3 ligase for the ubiquitin-like modifier FAT10, which inhibits Parkin activation and mitophagy. Cell Rep Mar 16;34(11):108857. doi: 10.1016/j.celrep.2021.108857.
Boehm AN, Bialas J, Catone N, Sacristan-Reviriego A, van der Spuy J, Groettrup M, Aichem A. 2020. The ubiquitin-like modifier FAT10 inhibits retinal PDE6 activity and mediates its proteasomal degradation. JBC Aug 14;jbc.RA120.013873. doi: 10.1074/jbc.RA120.013873. Online ahead of print.
Aichem A, Groettrup M. 2020. The ubiquitin-like modifier FAT10 - much more than a proteasome-targeting signal. J Cell Sci Jul 21;133(14):jcs246041.doi: 10.1242/jcs.246041.
Aichem A, Sailer C, Ryu S, Catone N, Stankovic-Valentin N, Schmidtke G, Melchior F, Stengel F, Groettrup M. 2019. The ubiquitin-like modifier FAT10 interferes with SUMO activation. Nat Commun Oct 1;10(1):4452. doi: 10.1038/s41467-019-12430-z.
Bialas J, Boehm AN, Catone N, Aichem A, Groettrup M. 2019. The ubiquitin-like modifier FAT10 stimulates the activity of the deubiquitylating enzyme OTUB1. J Biol Chem Feb 4. pii: jbc.RA118.005406. doi: 10.1074/jbc.RA118.005406. [Epub ahead of print].
Aichem A, Boehm AN, Catone N, Schmidtke G, Groettrup M. 2019. Analysis of modification and proteolytic targeting by the ubiquitin-like modifier FAT10. Methods Enzymol 618:229-256. doi: 10.1016/bs.mie.2018.12.040. Epub 2019 Feb 83.
Aichem A, Anders S, Catone N, Rößler P, Stotz S, Berg A, Schwab R, Scheuermann S, Bialas J, Schütz-Stoffregen MC, Schmidtke G, Peter C, Groettrup M, Wiesner S. 2018. The structure of the ubiquitin-like modifier FAT10 reveals an alternative targeting mechanism for proteasomal degradation. Nat Commun Aug 20;9(1):3321. doi: 10.1038/s41467-018-05776-3.
Schregle R, Mah MM, Mueller S, Aichem A, Basler M, Groettrup M. 2018. The expression profile of the ubiquitin-like modifier FAT10 in immune cells suggests cell type-specific functions. Immunogenetics Mar 5. doi: 10.1007/s00251-018-1055-5. [Epub ahead of print].
Sacristan-Reviriego A, Bellingham J, Prodromou C, Boehm AN, Aichem A, Kumaran N, Bainbridge J, Michaelides M, van der Spuy J. 2018. The integrity and organization of the human AIPL1 functional domains is critical for its role as a HSP90-dependent co-chaperone for rod PDE6. Hum Mol Genet Apr 1;27(7):1309. doi: 10.1093/hmg/ddy024.
Spinnenhirn V, Bitzer A, Aichem A, Groettrup M. 2016. Newly translated proteins are substrates for ubiquitin, ISG15 and FAT10. FEBS Lett. doi: 10.1002/1873-3468.12512. [Epub ahead of print].
Aichem A, Groettrup M. 2016. The ubiquitin-like modifier FAT10 in cancer development. Int J Biochem Cell Biol. Jul 5. pii: S1357-2725(16)30165-0. doi: 10.1016/j.biocel.2016.07.001. [Epub ahead of print]
Dufner A, Kisser A, Niendorf S, Basters A, Reissig S, Schönle A, Aichem A, Kurz T, Schlosser A, Yablonski D, Groettrup M, Buch T, Waisman A, Schamel WW, Prinz M, Knobeloch KP. 2015. The ubiquitin-specific protease USP8 is critical for the development and homeostasis of T cells. Nature Immunol. Jul 27. doi: 10.1038/ni.3230.
Bialas J, Groettrup M, Aichem A. 2015. Conjugation of the Ubiquitin Activating Enzyme UBE1 with the Ubiquitin-Like Modifier FAT10 Targets It for Proteasomal Degradation. PLoS One. Mar 13;10(3):e0120329. doi: 10.1371/journal.pone.0120329. eCollection 2015.
Spinnenhirn V, Farhan H, Basler M, Aichem A, Canaan A, Groettrup M. 2014. The ubiquitin-like modifier FAT10 decorates autophagy targeted Salmonella and contributes to resistance of mice. J Cell Sci Sep 30. pii: jcs.152371. [Epub ahead of print].
Aichem A, Catone N, Groettrup M. 2014. Investigations into the auto-FAT10ylation of the bispecific E2 conjugating enzyme USE1.FEBS J doi: 10.1111/febs.12745. [Epub ahead of print].
Schmidtke G, Aichem A, Groettrup M. 2013. FAT10ylation as a signal for proteasomal degradation. Biochim Biophys Acta Mol Cell Res 1843(1):97-102.
Aichem A, Kalveram B, Spinnenhirn V, Kluge K, Catone N, Johansen T, Groettrup M. 2012. The proteomic analysis of FAT10 substrates identifies p62/SQSTM1 as a substrate of FAT10ylation.J Cell Sci 125(19):4576-4585.
Aichem A, Groettrup M. 2012. Detection and analysis of FAT10 modification. Methods Mol Biol 832:125-32.
Rani N, Aichem A, Schmidtke G, Kreft S, Groettrup M. 2012. FAT10 and NUB1L bind the VWA domain of Rpn10 and Rpn1 to enable proteasome-mediated proteolysis. Nature Comm 2012 March 20;. doi: 10.1038/ncomms1752.
Thiel J, Kimmig L, Salzer U, Grudzien M, Lebrecht D, Hagena T, Draeger R, Völxen N, Bergbreiter A, Jennings S, Gutenberger S, Aichem A, Illges H, Hannan JP, Kienzler AK, Rizzi M, Eibel H, Peter HH, Warnatz K, Grimbacher B, Rump JA, Schlesier M. 2011. Genetic CD21 deficiency is associated with hypogammaglobulinemia. J Allergy Clin Immunol Oct 27. [Epub ahead of print].
Aichem A, Pelzer C, Lukasiak S, Kalveram B, Sheppard PW, Rani N, Schmidtke G, Groettrup M. 2010. USE1 is a bispecific conjugating enzyme for ubiquitin and FAT10, which FAT10ylates itself in cis. Nat Commun 1(2):1-10.
Hoefer MM, Aichem A, Knight AM, Illges H. 2008. Modulation of murine complement receptor type 2 (CR2/CD21) ectodomain shedding by its cytoplasmic domain. Mol Immunol 45(8):2127-2137.
Aichem A, Masilamani M, Illges H. 2006. Redox-regulation of CD21-shedding involves signaling via PKC and indicates the formation of a juxtamembrane stalk. J Cell Sci 119(Pt14):2892-2902.
Aichem A, Mutzel R. 2001. Unconventional mRNA processing in the expression of two calcineurin B isoforms in Dictyostelium. J Mol Biol 308:873-882.
Kessen U, Schaloske R, Aichem A, Mutzel R. 1999. Ca²⁺/Calmodulin-independent activation of calcineurin from Dictyostelium by unsaturated long chain fatty acids. J Biol Chem 274(53):37821-37826.
Sonnemann J, Aichem A, Schlatterer C. 1998. Dissection of the cAMP induced cytosolic calcium response in Dictyostelium discoideum: the role of cAMP receptor subtypes and G protein subunits. FEBS Letters 436:271-276.